Frequency and phenotypic characterization of CD66b⁺LDNs from solid tumor, lymphoma, or SLE patients. (A) Frequency of CD66b⁺ LDNs in PBMCs from HDs (n = 33) or patients with solid tumors (ST) (n = 17), lymphoma (L) (n = 28), or SLE patients (n = 9). Graph values indicate medians from independent experiments. Each symbol stands for a single HD or ST, L, or SLE patient. ***P ≤ .001, by 1-way ANOVA with the Dunnett posttest. (B-E) Representative FACS plots of CD11b and CD16 expression in CD10⁺ (R1) or CD10⁻ (R2) cells within CD66b⁺ LDNs from PBMCs of HDs (B), ST patients (C), L patients (D) or SLE patients (E). (F-G) Frequency of CD10⁺ LDNs within CD66b⁺ LDNs (F) or CD66b⁺ NDNs (G) from HD (n = 33), ST patients (n = 17), L patients (n = 28), or SLE patients (n = 9). Graph values indicate medians from independent experiments. Each symbol stands for a single HD, ST, L, or SLE patient. **P ≤ .01; ***P ≤ .001, by 1-way ANOVA with the Dunnett posttest. (H) CD3/CD28-stimulated T cells were cultured for 96 hours in the presence or absence of CD66b⁺ NDNs from HDs or CD66b⁺ NDNs and CD66b⁺ LDNs from SLE patients at a 5:1 neutrophil-to-T-cell ratio. The percentage of increase of T-cell proliferation, as measured by BrdU incorporation, is reported. Graph values indicate medians from independent experiments (n = 4). ***P ≤ .001, by 1-way ANOVA with the Dunnett posttest.